Altre lingue Easywell Biomedicals, Inc.

Azioni

1799

TW0001799005

Prodotti farmaceutici

Prezzo di chiusura Taipei Exchange Altri mercati azionari 06/03/2026			Variaz. 5gg	Var. 1 gen.
29,00 ^TWD	0,00%		-9,09%	-18,99%

13/11	Easywell Biomedicals, Inc. pubblica i risultati finanziari del terzo trimestre e dei primi nove mesi chiusi al 30 settembre 2025	CI
11/08/25	Easywell Biomedicals, Inc.: Risultati Finanziari del Secondo Trimestre e dei Primi Sei Mesi al 30 Giugno 2025	CI

Altre lingue

17/11	Artisan Therapeutics and Tulex Pharmaceuticals Announce Positive Phase 2a Results for ART-501, a Novel Oral Liquid Extended-Release Formulation for Autism Spectrum Disorder
13/11	Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
11/08/25	Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
12/05/25	Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
08/05/25	Easywell Biomedicals, Inc. announced that it expects to receive funding from Bayberry Management LLC and other investors
25/03/25	Easywell Biomedicals, Inc. announced that it expects to receive TWD 99.212 million in funding from Standard Chemical & Pharmaceutical Co. Ltd.
19/03/25	Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
12/03/25	Easywell Biomedicals, Inc. announced that it has received funding
17/12/24	Easywell Biomedicals, Inc. and Subsidiary Tulex Pharmaceuticals Inc. Signs a Co-Development Agreement for the TLX-050, and Adding a Third-Party Collaborator
12/11/24	Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
17/10/24	Easywell Biomedicals, Inc. announced that it expects to receive TWD 171.6 million in funding
23/09/24	Easywell Biomedicals, Inc.(TPEX:1799) added to S&P Global BMI Index
13/08/24	Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
07/08/24	Easywell Biomedicals, Inc. signed a letter of intent to acquire 40% stake in Jiangsu Huahan Pharmaceutical Technology Co.,Ltd. from Nanjing Huaxun Intellectual Property Consulting Co., Ltd. for CNY 37.5 million.
09/07/24	Easyway Biomedical Inc. and Tulex Pharmaceuticals Inc. Sign Collaborative Development Agreement with Handa Biotech and Its Subsidiary, Handa Neuroscience, LLC to Jointly Develop TLX-050
13/05/24	Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
08/05/24	Easywell Biomedicals, Inc. announced a financing transaction
07/04/24	Easywell Biomedicals, Inc.'s Subsidiary Jiangsu Huahan Pharma-Tech Co., Ltd. Obtains Approval from the Jiangsu Medical Products Administration of China for Compliance with the Good Manufacturing Practice Inspection for Pharmaceuticals
28/03/24	Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
13/11/23	Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11/08/23	Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
15/05/23	Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
30/03/23	Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
11/11/22	Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
12/08/22	Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022